Drugs / BSG005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04921254 | Aug 2021 → Mar 2023 | fungal infectious disease | Biosergen AS | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06678113 | Jul 2024 → Dec 2025 overdue | fungal infectious disease | Biosergen AS | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BSG005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04921254 ↗ |
| Route | Intravenous | “single IV infusion of ascending doses of BSG005 or placebo” NCT04921254 ↗ |